Tipiracil Hydrochloride/Trifluridine

盐酸替匹嘧啶/曲氟尿苷

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameTipiracil Hydrochloride/Trifluridine
Drug Alias NameTrifluridine/Tipiracil曲氟尿苷替吡拉西Tipiracil and TrifluridineTrifluridine and TipiracilTipiracil Hydrochloride and Trifluridine +[12] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitorsThymidine phosphorylase inhibitors
TargetsThymidine phosphorylaseDNA-directed DNA polymerase
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[16] 
Global Approved IndicationsStomach NeoplasmsColorectal Neoplasms
Approved Indications in ChinaColorectal Neoplasms
Original Approved Country/TerritoryJapan
Original Approved Date2014/03/24
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsYes TrifluridineTipiracil Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTaiho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdAdir SarlOhsu Knight Cancer Institute +[11] 
Inactive CompaniesBaylor Research Institute LlcThe University Of Texas MD Anderson Cancer CenterTakeda Pharmaceutical Co Ltd +[4] 
Active IndicationsLung NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[10] 
Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsGastrointestinal Neoplasms +[6] 

Other Information

ATC CodeL01BC
Related LinksWikipediaKEGG